Last reviewed · How we verify
AL (Coartem)
AL (Coartem) is a Artemisinin-based combination therapy (ACT) Small molecule drug developed by Centro de Investigacao em Saude de Manhica. It is currently FDA-approved for Uncomplicated malaria caused by Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi.
Coartem (artemether-lumefantrine) is a fixed-dose combination antimalarial that kills malaria parasites through artemether's rapid parasite clearance and lumefantrine's sustained blood schizonticide activity.
AL (Coartem) is a small molecule antimalarial medication used to treat malaria, specifically falciparum malaria. It is a combination of artemether and lumefantrine.
At a glance
| Generic name | AL (Coartem) |
|---|---|
| Sponsor | Centro de Investigacao em Saude de Manhica |
| Drug class | Artemisinin-based combination therapy (ACT) |
| Target | Parasite heme metabolism; hemozoin formation |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Artemether, a semi-synthetic artemisinin derivative, rapidly reduces parasite biomass by generating reactive oxygen species that damage parasite membranes and proteins. Lumefantrine, a long-acting aminoalcohol, inhibits parasite heme polymerization and provides sustained suppression of remaining parasites. Together they provide rapid symptom relief and complete parasite clearance with reduced recrudescence risk.
Approved indications
- Uncomplicated malaria caused by Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi
Common side effects
- Headache
- Fever
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Dizziness
- QT prolongation
Key clinical trials
- In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique (PHASE4)
- Efficacy of Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under 12 Years at Four Sentinel Sites in Mozambique (NA)
- Extended Duration Artemether-lumefantrine Treatment for Malaria in Children (PHASE4)
- The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination Therapy (PHASE4)
- Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali (PHASE2)
- Controlled Human Malaria Infection Transmission Model - Phase A (PHASE1, PHASE2)
- Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia (PHASE4)
- Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AL (Coartem) CI brief — competitive landscape report
- AL (Coartem) updates RSS · CI watch RSS
- Centro de Investigacao em Saude de Manhica portfolio CI
Frequently asked questions about AL (Coartem)
What is AL (Coartem)?
How does AL (Coartem) work?
What is AL (Coartem) used for?
Who makes AL (Coartem)?
What drug class is AL (Coartem) in?
What development phase is AL (Coartem) in?
What are the side effects of AL (Coartem)?
What does AL (Coartem) target?
Related
- Drug class: All Artemisinin-based combination therapy (ACT) drugs
- Target: All drugs targeting Parasite heme metabolism; hemozoin formation
- Manufacturer: Centro de Investigacao em Saude de Manhica — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Uncomplicated malaria caused by Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing